Latest Conference Articles

January 25th 2020, 2:00am

Gastrointestinal Cancers Symposium (ASCO GI)

The triplet combination of cabozantinib, nivolumab, and ipilimumab induced higher response rates, progression-free survival, and overall survival compared with nivolumab plus cabozantinib in patients with advanced hepatocellular carcinoma.

January 25th 2020, 12:58am

Gastrointestinal Cancers Symposium (ASCO GI)

The triplet of nivolumab, ramucirumab and paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer.

January 24th 2020, 10:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Teresa Macarulla, MD, discusses a new finding from the phase III POLO trial regarding patients who rapidly progressed on treatment.

January 24th 2020, 9:15pm

Gastrointestinal Cancers Symposium (ASCO GI)

The efficacy of larotrectinib has been confirmed in patients with heavily pretreated TRK fusion–positive gastrointestinal cancers.

January 24th 2020, 9:05pm

Gastrointestinal Cancers Symposium (ASCO GI)

Pembrolizumab monotherapy in the first and later lines of therapy leads to more durable responses and meaningfully improves overall survival compared with chemotherapy in patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages.

January 22nd 2020, 10:36pm

Gastrointestinal Cancers Symposium (ASCO GI)

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

January 6th 2020, 11:01pm

State of the Science Summit on Hematologic Malignancies

Seo-Hyun Kim, MD, discusses frontline treatment considerations in stage III and IV classical Hodgkin lymphoma and exciting combinations on the horizon.

January 3rd 2020, 11:08pm

State of the Science Summit on Hematologic Malignancies

Jamile M. Shammo, MD, FASCP, FACP, discusses the current treatment paradigm of myelofibrosis, criteria for ruxolitinib resistance and intolerance, and promising agents on the horizon.

January 3rd 2020, 9:21pm

State of the Science Summit on Hematologic Malignancies

Parameswaran Venugopal, MD, discusses current and emerging treatment strategies in non-Hodgkin lymphoma.

January 2nd 2020, 9:14pm

State of the Science Summit on Genitourinary Cancers

Nancy B. Davis, MD, discusses the excitement with targeted therapies as well as anticipated combination strategies under investigation in advanced urothelial cancer.

December 28th 2019, 4:00pm

San Antonio Breast Cancer Symposium

A high absolute lymphocyte count at baseline appears to be an independent predictor for longer overall survival in patients with metastatic breast cancer who are treated with eribulin mesylate.

December 28th 2019, 12:00am

State of the Science Summit on Hematologic Malignancies

Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.

December 22nd 2019, 4:00pm

State of the Science Summit on Hematologic Malignancies

Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.

December 17th 2019, 12:32am

State of the Science Summit on Hematologic Malignancies

Agne Paner, MD, discusses the treatment paradigm in multiple myeloma and promising agents on the horizon.

December 16th 2019, 2:53am

San Antonio Breast Cancer Symposium

Mathematical modeling was unable to harmonize the VENTANA SP263 and Dako 22C3 PD-L1 assays with the FDA-approved VENTANA PD-L1 SP142 companion diagnostic for the selection of patients with advanced triple-negative breast cancer appropriate for atezolizumab plus nab-paclitaxel.

December 16th 2019, 1:06am

San Antonio Breast Cancer Symposium

Patients with premenopausal breast cancer and discordant clinical and genomic risk had a small increase in distant metastasis if they did not receive adjuvant chemotherapy, according to a post hoc analysis of the MINDACT trial.

December 14th 2019, 5:38am

San Antonio Breast Cancer Symposium

Hope S. Rugo, MD, discusses the updated data from the phase III SOPHIA trial for patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies, presented at the 2019 San Antonio Breast Cancer Symposium.

December 14th 2019, 5:00am

San Antonio Breast Cancer Symposium

Adding the PARP inhibitor olaparib to neoadjuvant platinum based-chemotherapy was determined to be a safe treatment for patients with triple-negative breast cancer, as well as for patients with breast cancer whose tumors harbor germline BRCA mutations.

December 14th 2019, 3:59am

San Antonio Breast Cancer Symposium

Almost half of patients with high-risk luminal-B breast cancer converted to a low risk of recurrence following chemotherapy-free neoadjuvant therapy, matching the performance of standard chemotherapy in small randomized trial.

December 14th 2019, 2:05am

San Antonio Breast Cancer Symposium

The presence of circulating tumor DNA and circulating tumor cells following neoadjuvant chemotherapy can be an independent predictor of disease recurrence in patients with early triple-negative breast cancer.